Please use this identifier to cite or link to this item:
|Title:||Bridging Communities in the field of Nanomedicine|
|Authors:||HALAMODA KENZAOUI BLANKA; BACONNIER SIMON; BASTOGNE THIERRY; BAZILE DIDIER; BOISSEAU PATRICK; BORCHARD GERRIT; BORGOS SVEN EVEN; CALZOLAI LUIGI; CEDERBRANT KARIN; DI FELICE GABRIELLA; DI FRANCESCO TIZIANA; DOBROSVOLSKAIA MARINA; GASPAR ROGERIO; GRACIA BELEN; HACLEY VINCENT; LEYENS LADA; LIPTROTT NEILL; MARGRIET PARK; PATRI ANIL; ROEBBEN GERT; ROESSLEIN MATTHIAS; THUERMER RENE; URBAN LOPEZ PATRICIA; ZUANG VALERIE; BREMER SUSANNE|
|Citation:||REGULATORY TOXICOLOGY AND PHARMACOLOGY vol. 106 p. 187-196|
|Publisher:||ACADEMIC PRESS INC ELSEVIER SCIENCE|
|Type:||Articles in periodicals and books|
|Abstract:||An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled "Bridging communities in the Field of Nanomedicine" in Ispra/Italy on the 27th -28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing Horizon 2020 projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarized in the format of a survey.|
|JRC Directorate:||Health, Consumers and Reference Materials|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.